Frequently asked questions

Rejoyn is $200 for the full 6 weeks. If your patient’s insurance doesn’t cover Rejoyn, they can use REJOYN75 at the pharmacy checkout to get Rejoyn for $50.*

*The limited time offer is available until June 30, 2025, to those who do not pay for Rejoyn through insurance. Your patients may pay less if their insurance covers Rejoyn. The pharmacy will automatically check their coverage when processing the prescription.

Rejoyn end-to-end nurse support can answer questions about insurance coverage and reimbursement. Call 1-833-Y-REJOYN (1-833-973-5696), Monday through Friday, 8 AM to 8 PM ET, excluding holidays.

The following are topics you may want to cover with your patients. Rejoyn:

• Is the first and only add-on prescription treatment for depression symptoms that’s an app¹
• Is authorized by the FDA¹
• Provides 6 weeks of brain-training exercises and short skills-based therapy lessons¹
• Reduced symptoms without side effects related to Rejoyn in a clinical trial (when added to an antidepressant)¹
• Taps into the brain's natural ability to change (known as neuroplasticity)^2,3

Visit the patient site for more patient-friendly resources.

Patients should plan to use Rejoyn 3 to 6 days a week for 6 weeks. Completing the CET brain-training exercises in Rejoyn takes about 20-30 minutes each, and the CBT-based video lessons take about 5 minutes each. Patients access treatment on their smartphone, on their own time. New exercises are unlocked at midnight the day they become available and expire at the end of each week. It’s important to note that at the end of each week, patients will lose access to the previous week’s exercises. They will, however, retain access to any lessons that have yet to be completed.

It’s OK to let your patients know that they may find the exercises challenging. Remind them that it’s not about the number of matches they make—as long as they are consistently completing the exercises, they’re doing them correctly. You can find more information to share with your patients here.

CBT=cognitive behavioral therapy; CET=cognitive-emotional training.

Nurse support, including adherence support, is available for your patients. Patients can opt in through the app at any time and agree to share data about their treatment with the nurse support program. Rejoyn end-to-end nurse support can provide patients with support calls to help them stay on track.

Results from the clinical trial suggest that patients who consistently completed the exercises and finished the program could benefit most from Rejoyn. In a clinical trial, 88.1% of patients (n=177) adhered to Rejoyn, completing at least 12 of the 18 treatment sessions.²

Let your patients know that Rejoyn Patient Support nurses are available to help check in on patient progress and help them stay on track at no charge.

If at any point you or your patients have questions about Rejoyn, call 1-833-Y-REJOYN (1-833-973-5696) to speak with a nurse Monday through Friday, 8 AM to 8 PM ET, excluding holidays.

Rejoyn is a prescription digital therapeutic for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. It is intended to reduce MDD symptoms.² Read more about Rejoyn here.

Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.²

Rejoyn does not monitor the patient’s symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.²

Recent research suggests neural network disruption can cause MDD symptoms. Imaging of patients with MDD shows hyperactivity in emotion centers like the amygdala and hypoactivity in cognitive areas like the prefrontal cortex. Rejoyn is different from medication and psychotherapy in that it was designed specifically to target dysregulated connectivity between these 2 regions, strengthening the connections between them. Read more here.^1,2

Yes, you can experience CET firsthand at an upcoming congress:

• APA | Los Angeles, California | May 17 to May 21, 2025
• Psych Congress | San Diego, California | September 17 to September 21, 2025

Rejoyn is authorized by the FDA for the treatment of adults age 22+ with MDD who are on antidepressant medication.^1,2

Read about the safety and efficacy of Rejoyn here.

There were zero adverse events related to Rejoyn in a clinical trial of Rejoyn added to an antidepressant. Learn more about the safety and efficacy of Rejoyn here.²

Safety Information for Rejoyn

Rejoyn is not intended to be used as a standalone therapy or a substitute for medication. Patients should continue their current treatment as directed.

Rejoyn does not monitor the patient's symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber. Patients should be clearly instructed that if they believe their depression is worsening or if they have feelings or thoughts of harming themselves or others, to contact a healthcare professional, dial 911 or go to the nearest emergency room immediately.

Rejoyn is indicated to be an adjunct to antidepressant medication. Adding Rejoyn to your patient’s care plan helps target dysregulated connectivity between the amygdala and the prefrontal cortex—all from a smartphone. Rejoyn is not intended to be used as a standalone therapy or a substitute for medications. Patients should continue their current treatment as directed.¹

Otsuka Precision Health (OPH) is committed to protecting the privacy and security of your patient's information. OPH may use, store, and share your patient's data as described in the OPH Privacy Policy and in a manner consistent with your patient's privacy choices, including how your patient can correct, change or delete certain personal information OPH collects about them in connection with their use of this live chat service. Please see OPH Privacy Policy for more information.

You can learn more by attending a peer-led virtual program. During the program, you will:

• Gain insight into the need for innovative treatment options for MDD symptoms
• Explore the clinical evidence supporting the efficacy and safety of Rejoyn
• Learn how to prescribe Rejoyn to augment your patient's antidepressant medication
• Participate in a live Q&A session

Register for the program here.

Combining the rigor of pharma with a data-first focus on patient experience, Otsuka Precision Health, Inc. (OPH) focuses on bringing to market prescription digital therapeutics and other innovative technologies, and provides nonpromotional patient support services. The company is committed to personalizing care, unlocking doors to access, and uniting a fragmented experience. OPH’s current focus areas include a variety of technological interventions that help unearth personal health needs and address them as a true collaborator within the broader healthcare ecosystem.

OPH is a subsidiary of Otsuka America, Inc. (Otsuka), which is a subsidiary of Otsuka Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan.

For more information, please visit www.otsuka-oph.com.

Click Therapeutics, Inc., is a pioneering company that designs, develops, and validates software used as prescription medical treatments for people with unmet medical needs. As a leader in digital therapeutics, Click Therapeutics offers accessible, proven, and FDA-regulated prescription treatments directly to patients' smartphones. The company focuses on both scientific excellence and patient-centered design, creating engaging experiences that lead to meaningful health improvements. Using advanced tools like artificial intelligence and machine learning, Click Therapeutics continually enhances its platform with innovative methods that help support positive changes in thinking and behavior. Their digital treatments cover a wide range of health areas, including mental health, brain conditions, cancer, immune system disorders, and diseases related to heart health and metabolism.

For more information, visit www.clicktherapeutics.com.